Our capital strategy
Our capital strategy is a combination of non-dilutive funding sources and equity capital to finance the development of the Company’s vaccine candidates.
- In 2021, Valneva raised approximately $210 million through a successful Nasdaq IPO with a concurrent private placement in Europe and a successful follow-on equity offering in the U.S. and Europe.
- Valneva’s ordinary shares are listed on Euronext Paris under the symbol “VLA” and its ADSs are listed on the Nasdaq Global Select Market under the symbol “VALN”. The ADSs began trading on the Nasdaq Global Select Market on May 6, 2021.